Jacob Sands, MD

Jacob Sands, MD

Dana-Farber Cancer Institute

Latest Content

Overview of treatment standards for small cell lung cancer (SCLC) across limited- and extensive-stage disease, highlighting current care practices and expert insights.

Videos & Podcasts

05/05/2026

Standard of Care in SCLC: Treatment Across Limited- and Extensive-Stage Disease

Jacob Sands, MDRahul Gosain, MD, MBARohit Gosain, MD
Toxicity awareness in novel antibody-drug conjugates and NSCLC, featuring expert insights from Dr. Jacob Sands, Dr. Rohit Gosain, and Dr. Rahul Gosain on key adverse effects and safety considerations.

Videos & Podcasts

01/02/2026

Key Adverse Effects of Novel Antibody-Drug Conjugates in NSCLC

Jacob Sands, MDRahul Gosain, MD, MBARohit Gosain, MD
FDA approves Dato-DXd for EGFR-mutated NSCLC patients - latest oncology update from OncUpdates.

Videos & Podcasts

08/18/2025

FDA Approves Dato-DXd for Patients With EGFR-Mutated NSCLC

Jacob Sands, MDRahul Gosain, MD, MBARohit Gosain, MD